Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 9/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101580 | 0.84 | CYP1A2 (0.45) | MAT2ANTRK1RXRAPRMT5 | |
| SCHEMBL6355198 | 0.80 | TACR1 (0.39) | MAT2AMAPK8MAPK9NTRK1MTNR1A | |
| SCHEMBL5101584 | 0.80 | NTRK1 (0.40) | MAT2AMAPK8MAPK9NTRK1PRMT5 | |
| SCHEMBL5089786 | 0.75 | TACR1 (0.43) | MTNR1AMTNR1BTACR1MEN1TP53 | |
| SCHEMBL5093108 | 0.74 | MAT2A (0.37) | MAT2AMTNR1AMTNR1BRXRATACR1 | |
| SCHEMBL5089907 | 0.72 | HTR6 (0.44) | MAT2ANTRK1MTNR1AMTNR1BTACR1 | |
| SCHEMBL28888717 | 0.72 | MAT2A (0.41) | MAT2ANTRK1MTNR1AMTNR1BTACR1 | |
| SCHEMBL5101221 | 0.72 | TACR1 (0.36) | MTNR1AMTNR1BRXRATACR1LMNA | |
| SCHEMBL5094791 | 0.70 | TACR1 (0.43) | MTNR1AMTNR1BTACR1LMNAMAPT | |
| Dimethylamine SCHEMBL5095643 | 0.67 | PTPN1 (0.39) | MAPK8NTRK1MTNR1AMTNR1BRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317035-B2 | Tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-01-08 | — | — | US | disclosed |
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | TPH1, HTR1A, HTR5A | MAT2A 845/4885MAPK8 4480/4885MAPK9 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.